Briaire-de Bruijn I - Search Results

1

VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation.

Luk SJ, Schoppmeyer R, Ijsselsteijn ME, Somarakis A, Acem I, Remst DFG, Cox DT, van Bergen CAM, Briaire-de Bruijn I, Grönloh MLB, van der Meer WJ, Hawinkels LJAC, Koning RI, Bos E, Bovée JVMG, de Miranda NFCC, Szuhai K, van Buul JD, Falkenburg JHF, Heemskerk MHM. Luk SJ, et al. Among authors: briaire de bruijn i. Cancer Immunol Res. 2023 Nov 1;11(11):1480-1492. doi: 10.1158/2326-6066.CIR-22-0759. Cancer Immunol Res. 2023. PMID: 37695550

2

Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C.

Rozeman LB, Sangiorgi L, Briaire-de Bruijn IH, Mainil-Varlet P, Bertoni F, Cleton-Jansen AM, Hogendoorn PC, Bovée JV. Rozeman LB, et al. Hum Mutat. 2004 Dec;24(6):466-73. doi: 10.1002/humu.20095. Hum Mutat. 2004. PMID: 15523647

3

Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition.

Willems SM, Schrage YM, Baelde JJ, Briaire-de Bruijn I, Mohseny A, Sciot R, Bovée JV, Hogendoorn PC. Willems SM, et al. Histopathology. 2008 Mar;52(4):465-74. doi: 10.1111/j.1365-2559.2008.02967.x. Histopathology. 2008. PMID: 18315599

4

Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.

Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, Hogendoorn PC, Bovée JV. Schrage YM, et al. Cancer Res. 2009 Aug 1;69(15):6216-22. doi: 10.1158/0008-5472.CAN-08-4801. Epub 2009 Jul 14. Cancer Res. 2009. PMID: 19602594

5

Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC. Mohseny AB, et al. J Pathol. 2009 Nov;219(3):294-305. doi: 10.1002/path.2603. J Pathol. 2009. PMID: 19718709

6

COX-2 expression in chondrosarcoma: a role for celecoxib treatment?

Schrage YM, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker BE, Taminiau AH, Kalinski T, Llombart-Bosch A, Bovée JV. Schrage YM, et al. Eur J Cancer. 2010 Feb;46(3):616-24. doi: 10.1016/j.ejca.2009.11.002. Epub 2009 Dec 11. Eur J Cancer. 2010. PMID: 20004565

7

Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.

van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JV. van Oosterwijk JG, et al. Ann Oncol. 2012 Jun;23(6):1617-26. doi: 10.1093/annonc/mdr512. Epub 2011 Nov 23. Ann Oncol. 2012. PMID: 22112972 Free article.

8

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.

van Oosterwijk JG, van Ruler MA, Briaire-de Bruijn IH, Herpers B, Gelderblom H, van de Water B, Bovée JV. van Oosterwijk JG, et al. Br J Cancer. 2013 Sep 3;109(5):1214-22. doi: 10.1038/bjc.2013.451. Epub 2013 Aug 6. Br J Cancer. 2013. PMID: 23922104 Free PMC article.

9

NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.

Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ, Nielsen TO. Endo M, et al. Mod Pathol. 2015 Apr;28(4):587-95. doi: 10.1038/modpathol.2014.155. Epub 2014 Nov 21. Mod Pathol. 2015. PMID: 25412843 Free article.

10

Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.

Cleven AH, Zwartkruis E, Hogendoorn PC, Kroon HM, Briaire-de Bruijn I, Bovée JV. Cleven AH, et al. Histopathology. 2015 Oct;67(4):483-90. doi: 10.1111/his.12666. Epub 2015 Mar 23. Histopathology. 2015. PMID: 25648524

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page